Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 032 - CARSgen

Next Previous
Search
Drug Profile

CT 032 - CARSgen

Alternative Names: Anti-CD19 chimeric antigen receptor T cell therapy - CARsgen; CAR-CD19 T cells - CARsgen; CD19 Redirected Autologous Cells - CARsgen; CT-032 - CARSgen; CT032 CAR-CD19 T cells - CARsgen

Latest Information Update: 18 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Developer CARsgen; Renji Hospital
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Lymphoid leukaemia

Most Recent Events

  • 27 May 2021 CARsgen Therapeutics completes the phase I/II trial in Non-Hodgkin's B Cell Lymphoma (Refractory metastatic disease, Second-line therapy or greater) in China (NCT03994913)
  • 28 Feb 2020 No recent reports of development identified for phase-I development in Lymphoid-leukaemia in China (IV)
  • 27 Sep 2019 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Refractory metastatic disease) in China (IV) (NCT03994913)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top